Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
6 evidence topics · 5 sources
Summary
The roles of complement and FcRn inhibitors are being established, especially in patients unresponsive to conventional therapy; Gilhus et al. (2024) recommend them, because of high drug costs, only for difficult-to-treat patients with severe myasthenia gravis not responding to standard immunosuppressive treatment, and as second- or third-line treatment in severe exacerbations and crisis. The company positions claseprubart as a potential first-line biologic intended to displace C5 complement inhibitors and compete with FcRn blockers, and notes that the C5 efficacy data it compares against come from different trials with different designs and populations. Its target profile is a single self-administered 300 mg/2 mL subcutaneous autoinjector dosed every 2 or 4 weeks, without a boxed warning or REMS; the every-4-week arm and a QMG inclusion criterion were added to the phase 3 trial after a post hoc analysis of MaGic. The company proposes that selective inhibition of the classical pathway may lower the risk of infection from encapsulated bacteria by preserving the lectin and alternative pathways.
Company positioning against complement C5 inhibitors and FcRn blockers
Company target product profile: no Boxed Warning or REMS and self-administered autoinjector
Every-4-week subcutaneous dosing evaluated in the phase 3 trial
Biologic market growth anticipated by the company
Guideline positioning of complement and FcRn therapies
“several clinical trials have been published for newer targeted therapies in MG, predominantly those that inhibit the complement and neonatal Fc gamma receptor pathways, the roles of which are being slowly established especially in patients unresponsive to conventional therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote